Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy.
Head Neck. 2016 Dec 29;:
Authors: Okoye CC, Bucher J, Tatsuoka C, Parikh SA, Oliveira GH, Gibson MK, Machtay M, Yao M, Zender CA, Dorth JA
Abstract
BACKGROUND: The underlying contributors to cardiovascular disease (CVD) in patients with head and neck squamous cell carcinoma (HNSCC) are poorly characterized.
METHODS: Patients with HNSCC who underwent definitive or adjuvant (chemo)radiation between 2011 and 2013 were retrospectively reviewed. The 10-year risk estimates for a CVD event were calculated according to the Framingham Risk Score (FRS).
RESULTS: One hundred fifteen patients with predominantly stage III/IV HNSCC had a median follow-up of 2 years. At diagnosis, 23% of patients had CVD. The FRS was higher among patients with laryngeal cancer versus other sites (20.5% vs 14.4%). Twenty-four percent of all patients had uncontrolled blood pressure at diagnosis. Among the patients with CVD, 41% were not taking antiplatelet therapy and 30% were not taking statin therapy. Thirty-four percent of patients without CVD had indications for initiating statin therapy.
CONCLUSION: Patients with HNSCC have a high baseline CVD risk and many do not receive optimal preventive care. © 2016 Wiley Periodicals, Inc. Head Neck, 2016.
PMID: 28032680 [PubMed - as supplied by publisher]
http://ift.tt/2ikwqnF
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου